ECCO 2022
Bienvenue
Ulcerative colitis clinical trials on treatment effects: a comparison of clinical, endoscopic and histological remission (ECCO 2022)
15/03 - Clinical remission, defined by the Mayo Clinic Score (MCS) or modified MCS, is the accepted regulatory endpoint in drug development for ulcerative colitis (UC). Whilst histologic remission is a more stringent outcome, recent trials have reported numerically higher rates compared to endoscopic or clinical remission rates at the same timepoint, suggesting that histologic remission may be ...
Inscrivez-vous gratuitement
Afin d'accéder à l'info médicale nationale et internationale sur tous vos écrans.
Vaccination against SARS-COV-2 infection in IBD patients: should we prioritize an additional booster injection? (ECCO...
On the way to Crohn's disease and ulcerative colitis control: fatigue as part of a novel composite endpoint (ECCO 2022)
Insights from patients with Ulcerative Colitis on disease burden Findings from a real-world survey in Europe (ECCO 2022)
'Superdonor' Samples Don't Increase FMT Success in Ulcerative Colitis (ECCO 2022)
Two Factors Linked to Higher Risk of Long COVID in IBD (ECCO 2022)